3 results
Approved WMOPending
This study is being performed to evaluate the cognitive and psychomotor effects of the new compound LY2624803 after bedtime dosing.
Not approvedWill not start
To assess the safety, tolerability, biomarker and cognitive efficacy of investigational products in subjects who are known to have an Alzheimer*s disease-causing mutation by determining if treatment with the study drug slows the rate of progression…
Not approvedWill not start
Assess cognitive efficacy of gantenerumab, solanezumab in individuals who have mutations causing dominantly inherited Alzheimer's disease as measured by change in the DIAN-TU cognitive composite score between baseline and a minimum of 4 years.…